ABL kinase inhibitors are highly effective for BCR-ABL-positive leukemias such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here, ABL1 is linked to leukemia.